31 reports of this reaction
4.7% of all BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE reports
#2 most reported adverse reaction
HAEMORRHAGIC STROKE is the #2 most commonly reported adverse reaction for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, manufactured by Foundation Consumer Brands. There are 31 FDA adverse event reports linking BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE to HAEMORRHAGIC STROKE. This represents approximately 4.7% of all 662 adverse event reports for this drug.
Patients taking BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE who experience haemorrhagic stroke should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMORRHAGIC STROKE is moderately reported among BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE users, representing a notable but not dominant share of adverse events.
In addition to haemorrhagic stroke, the following adverse reactions have been reported for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE:
The following drugs have also been linked to haemorrhagic stroke in FDA adverse event reports:
HAEMORRHAGIC STROKE has been reported as an adverse event in 31 FDA reports for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMORRHAGIC STROKE accounts for approximately 4.7% of all adverse event reports for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, making it one of the most commonly reported side effect.
If you experience haemorrhagic stroke while taking BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.